Summary by Moomoo AI
On February 28, 2024, 180 Life Sciences Corp. announced the appointment of Blair Jordan to its Board of Directors. Jordan, deemed independent according to Nasdaq Capital Market rules, will serve as a Class II director until the 2024 Annual Meeting of Stockholders. Concurrently, the Board set its membership at four and continues to seek qualified independent directors. Jordan brings extensive experience, including his current role as CEO of HighMont Advisors Inc. and senior advisor at Evans & Evans, Inc. His previous positions include CFO and interim CEO at Ascent Industries Corp., and he has served on multiple boards across various sectors. Jordan's appointment includes membership on several Board committees and he will receive an annual retainer fee, with half of his compensation deferred until the company raises $1 million. The company will enter into an indemnification agreement with Jordan, similar to those with other directors.